Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on CervoMed and keeping the price target at $25.00.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Ram Selvaraju has given his Buy rating due to a combination of factors related to CervoMed’s lead asset, neflamapimod, and the company’s advancing clinical strategy. He highlights the imminent readouts from the Phase 2a study in non-fluent primary progressive aphasia, with near-term biomarker data and subsequent 24-week clinical results expected to further clarify the drug’s potential in frontotemporal dementia.

Selvaraju also emphasizes the upcoming pivotal development in dementia with Lewy bodies, supported by FDA-aligned trial design, extended patent protection through 2042, and favorable regulatory recognition via the U.K.’s ILAP Innovation Passport. He points to supportive Phase 2b data, including exposure–response and PK/PD analyses that underpin the selected Phase 3 dose, and maintains his conviction that these catalysts justify reiterating a Buy rating and an unchanged $25 price target.

Selvaraju covers the Healthcare sector, focusing on stocks such as CervoMed, Urogen Pharma, and Brainsway. According to TipRanks, Selvaraju has an average return of 25.5% and a 59.20% success rate on recommended stocks.

In another report released on August 10, Canaccord Genuity also reiterated a Buy rating on the stock with a $18.00 price target.